Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 3Phase NA 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 22Breast Neoplasms 19Lymphoma 14Sarcoma 13Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 8Lymphoma, B-Cell 8Hodgkin Disease 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Immunoblastic Lymphadenopathy 5Ovarian Neoplasms 4Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Hepatocellular 4Recurrence 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Primary Effusion 3Chondrosarcoma 3Triple Negative Breast Neoplasms 2Solitary Fibrous Tumors 2Sarcoma, Clear Cell 2Plasmablastic Lymphoma 2Osteosarcoma 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Liver Neoplasms 2

Interventions

fludarabine phosphate 4Cyclophosphamide 4Rituximab 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3Filgrastim 3Etoposide 3Cyclosporine 3venetoclax 2Whole-Body Irradiation 2Ifosfamide 2Cord Blood Stem Cell Transplantation 2Carboplatin 2veltuzumab 1pirtobrutinib 1pevonedistat 1ocaratuzumab 1iratumumab 1fludarabine 1etoposide phosphate 1aldesleukin 1Vincristine 1Tacrolimus 1Sirolimus 1Psychiatric Rehabilitation 1Prednisone 1Microarray Analysis 1Methotrexate 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Dendritic Cell Sarcoma, Interdigitating × Doxorubicin × Clear all
NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡